EMEA-002952-PIP01-21

Table of contents

Key facts

Active substance
Bamlanivimab
Therapeutic area
Infectious diseases
Decision number
P/0221/2021
PIP number
EMEA-002952-PIP01-21
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Intravenous use
Contact for public enquiries
Eli Lilly and Company Limited

E-mail: vowles_marcia@lilly.com
Tel. +44 (0) 0125631500

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating